Drugs / Ocoxin-Viusid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03576521 | May 2015 → Jan 2018 | breast carcinoma, chemotherapy-induced toxicity | Catalysis SL | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ocoxin-Viusid | “Evaluation of Ocoxin®-Viusid® in Breast Cancer” NCT03576521 ↗ |
| Modality | Other / unclassified | “Ocoxin-Viusid nutritional supplement” NCT03576521 ↗ |
| Route | Oral | “Ocoxin-Viusid oral solution” NCT03576521 ↗ |